During an inspection on May 3, 2024, the Food and Drug Administration issued two citations to Grifols Biologicals, LLC in Los Angeles concerning their handling of blood and blood products, according to data posted on the FDA’s website.
The FDA website indicates that the citations were delivered to the company as follows:
- ‘Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.’
- ‘Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.’
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
